Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Other hematologic neoplasm 1Lymphoid 1CNS 1

Conditions

Multiple Myeloma 2Breast Neoplasms 2Uterine Cervical Dysplasia 1Sarcoma 1Polycystic Ovary Syndrome 1Peripheral Nervous System Diseases 1Neuroblastoma 1Neoplasms 1Neoplasm Metastasis 1Lymphoma 1Leukemia 1Insulin Resistance 1Diabetes Mellitus 1Central Nervous System Neoplasms 1Cardiovascular Diseases 1Cardiotoxicity 1Burns 1

Interventions

Radiotherapy 122Temozolomide 110Carboplatin 53Filgrastim 46Vincristine 43Etoposide 39Cyclophosphamide 37Chemotherapy, Adjuvant 37Cisplatin 36Carmustine 32Irinotecan 27Peripheral Blood Stem Cell Transplantation 25Magnetic Resonance Spectroscopy 24Lomustine 22Thiotepa 21Methotrexate 20Granulocyte Colony-Stimulating Factor 18Procarbazine 16Bevacizumab 16Surgical Procedures, Operative 15O(6)-benzylguanine 14etoposide phosphate 13Drug Therapy 13Topotecan 12Paclitaxel 12Ifosfamide 12Thalidomide 11Radiation 11sargramostim 10Specimen Handling 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Central Nervous System Neoplasms × Fenofibrate × Clear all
NCT00357500 2014-10-01

Etoposide, Cyclophosphamide, Thalidomide, Celecoxib, and Fenofibrate in Relapsed or Progressive Cancer

Dana-Farber Cancer Institute

Phase 2 Completed
101 enrolled 10 charts
CNSLymphoidOther hematologic neoplasmSarcoma

Leukemia, Lymphoma, Neuroblastoma, Sarcoma, Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡